In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acucela Inc.

Division of Kubota Pharmaceutical Holdings Co. Ltd.
www.acucela.com

Latest From Acucela Inc.

Horama's Gene Therapies For Retinal Diseases: Fast Followers?

French biotech Horama has built-up its executive team and has two potential gene therapies for retinitis pigmentosa nearing the clinic.

Clinical Trials Ophthalmic

Pipeline Watch: Phase III Trials For Daprodustat, Rovalpituzumab Tesirine

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Research & Development Approvals

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

2016 Review: Refocus, Reduce, Reform The Watchwords In Japan

While reimbursement pricing issues and policies dominated the Japanese pharma market in 2016, there was also notable commercial activity during the year, although this was more about refocusing and reducing rather than major mergers and acquisitions.

Japan Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kubota Pharmaceutical Holdings Co. Ltd.
  • Senior Management
  • Ryo Kubota, MD, PhD, Chmn., Pres. & CEO
    John Gebhart, CFO
    Ted Danse, CBO
    Lukas Scheibler, PhD, EVP, R&D
  • Contact Info
  • Acucela Inc.
    Phone: (206) 805-8300
    1301 Second Ave., Ste. 4200
    Seattle, WA 98101-3805
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register